Related Experiment Video
Updated: Jul 29, 2026

Methods and Tips for Intravenous Administration of Adeno-associated Virus to Rats and Evaluation of Central Nervous System Transduction
Published on: August 25, 2017
alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding.
1Division of Medicine, Section of Respiratory Therapy, Cleveland Clinic Lerner School of Medicine, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. stollej@ccf.org
Intravenous augmentation therapy is effective for alpha-1 antitrypsin deficiency, but its cost-effectiveness and adverse events require careful consideration for patient management.
Area of Science:
- Biochemistry
- Clinical Medicine
- Pharmacoeconomics
Background:
- Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder leading to lung and liver disease.
- Intravenous augmentation therapy (IAT) is a primary treatment for AATD, aiming to increase AAT levels.
- Understanding the comprehensive profile of IAT is crucial for clinical practice.
Purpose of the Study:
- To review the biochemical and clinical efficacy of IAT in AATD.
- To evaluate the adverse events associated with IAT.
- To discuss the cost-effectiveness of IAT for AATD patients.
Main Methods:
- Literature review of existing studies on IAT in AATD.
- Analysis of biochemical markers and clinical outcomes reported in the literature.
- Examination of reported adverse events and economic evaluations.
Main Results:
- IAT demonstrates biochemical efficacy by increasing serum AAT levels.
- Clinical benefits of IAT include slowing lung function decline in certain AATD phenotypes.
- Adverse events are generally manageable, but vary in frequency and severity.
Conclusions:
- IAT is a valuable therapeutic option for AATD, offering biochemical and clinical benefits.
- A thorough assessment of potential adverse events and cost-effectiveness is essential for treatment decisions.
- Further research into optimizing IAT and exploring alternative therapies is warranted.
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
06:15Murine Intrapulmonary Tracheal Transplantation: A Model for Investigating Obliterative Airway Disease After Lung Transplantation
Published on: November 10, 2023
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Heart Failure VI: Adjunct Therapies
Venous Thrombosis III: Interprofessional Care